|Articles|June 1, 2009

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2009
  • Volume 0
  • Issue 0

Jean-Marc Huet, Bristol-Myers Squibb

There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face.

Jean-Marc Huet

CFO and Executive Vice President, Bristol-Myers Squibb

There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face. That's why BMS is executing a clear strategy to become a leading biopharma company while remaining focused on operational excellence and strengthening our balance sheet. What is needed now more than ever is the ability to turn challenges into opportunities; we're working to make sure BMS is well positioned to do so.

An innovative environment naturally creates leadership, and provides opportunities for successful, driven people. I make sure that the people whom I work with have what they need in order to be successful. We're all doers here, and that spirit will help us transform into the biopharma company we know we can be.

Articles in this issue

over 16 years ago

Hans Bishop, Bayer Healthcare

over 16 years ago

Jennifer Spear Smith, Wyeth

over 16 years ago

Stefan Platz, Roche

over 16 years ago

On the Right Pathways

over 16 years ago

Craig Dashefsky, Schering-Plough

over 16 years ago

Joe Mclane, Merck

over 16 years ago

Frank Karbe, Exelixis

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.